TerminatedPhase 2

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stopped: PI left the institution

United States5 participantsStarted 2013-01

Plain-language summary

This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Plasmacytomas on tissue biopsy
✓. Bone marrow plasmacytosis (\> 30% plasma cells)
✓. Monoclonal immunoglobulin spike on serum electrophoresis (immunoglobin G \[IgG\] \> 3.5 G/dL or immunoglobin A \[IgA\] \> 2.0 G/dL) or kappa or lambda light chain excretion \> 1 G/day on 24 hour urine protein electrophoresis
✓. Bone marrow plasmacytosis (10 to 30% plasma cells)
✓. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
✓. Lytic bone lesions
✓. Normal immunoglobin M (IgM) \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL

What they're measuring

Percentage of Patients Who Have Responded

Timeframe: 8 weeks

Trial details

NCT IDNCT01676961

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-11

Results submitted2017-08-03

View on ClinicalTrials.gov More Refractory Multiple Myeloma trials